Corneal fluorescein staining scores improve at 12 weeks after cyclosporine treatment

Patients with severe keratitis in dry eye disease experienced statistically significant reductions in corneal fluorescein staining scores after treatment with cyclosporine, according to 3-month data from the PERSPECTIVE study.

Santen presented the study data at the European Society of Ophthalmology congress. The ongoing, non-interventional prospective study evaluated the effectiveness, tolerability and safety of cyclosporine for the treatment of severe keratitis in patients with dry eye disease who failed to respond to previous artificial tear treatments.

The 3-month data showed statistically significant reductions in mean corneal fluorescein staining (CFS) scores. At baseline, 162 patients had a mean CFS score of 2.64, which improved to 1.77 in 94 patients at week 4 (P < .001) and to 1.36 in 117 patients at week 12 (P < .001), according to a Santen press release.

At week 4, 71.8% of patients showed improvement in CFS grade compared with 22.9% of patients who showed no improvements. At week 12, 75% of patients experienced CFS grade improvements compared with 23.1% of patients who experienced no improvement.

Subjective symptoms, such as foreign body sensation and blurred vision, were improved at weeks 4 and 12.

By week 12, conjunctival erythema was reduced in 45.8% of patients or unchanged in 46.6% of patients from baseline, according to the release.

Patients with severe keratitis in dry eye disease experienced statistically significant reductions in corneal fluorescein staining scores after treatment with cyclosporine, according to 3-month data from the PERSPECTIVE study.

Santen presented the study data at the European Society of Ophthalmology congress. The ongoing, non-interventional prospective study evaluated the effectiveness, tolerability and safety of cyclosporine for the treatment of severe keratitis in patients with dry eye disease who failed to respond to previous artificial tear treatments.

The 3-month data showed statistically significant reductions in mean corneal fluorescein staining (CFS) scores. At baseline, 162 patients had a mean CFS score of 2.64, which improved to 1.77 in 94 patients at week 4 (P < .001) and to 1.36 in 117 patients at week 12 (P < .001), according to a Santen press release.

At week 4, 71.8% of patients showed improvement in CFS grade compared with 22.9% of patients who showed no improvements. At week 12, 75% of patients experienced CFS grade improvements compared with 23.1% of patients who experienced no improvement.

Subjective symptoms, such as foreign body sensation and blurred vision, were improved at weeks 4 and 12.

By week 12, conjunctival erythema was reduced in 45.8% of patients or unchanged in 46.6% of patients from baseline, according to the release.